{
    "Trade/Device Name(s)": [
        "extendSURE\u2122 Lyophilized Hemoglobin A1c Linearity Controls",
        "Glycated Hemoglobin A1c Linearity Controls"
    ],
    "Submitter Information": "Canterbury Scientific Ltd",
    "510(k) Number": "K071648",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003030"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJX"
    ],
    "Summary Letter Date": "July 26, 2007",
    "Summary Letter Received Date": "July 30, 2007",
    "Submission Date": "May 22, 2007",
    "Regulation Number(s)": [
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Human whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Bayer DCA 2000",
        "BioRad Variant Classic",
        "Olympus AU Series",
        "Primus CLC 385"
    ],
    "Method(s)/Technology(ies)": [
        "Lyophilization"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Reference Material"
    ],
    "Document Summary": "FDA 510(k) summary for extendSURE Lyophilized Hemoglobin A1c Linearity Controls to verify HbA1c assay linearity using human whole blood controls",
    "Indications for Use Summary": "For in vitro diagnostic use only; intended to verify the linearity of HbA1c assays across the patient reportable range (4 to 18% NGSP aligned) using protocols established in individual laboratories",
    "fda_folder": "Clinical Chemistry"
}